EPISODE · Jun 20, 2026 · 58 MIN
Drug Pricing, Broken Incentives, and the 340b program Fixes Washington Won't Touch
from The Doctor's Lounge · host The Doctor's Lounge
Episode SummaryRyan Long — former senior policy advisor to Speaker Kevin McCarthy and current non-resident senior scholar at the USC Schaefer Institute — joins Drs. Koka and DiGiorgio for a deep dive into the structural failures driving American drug pricing. The conversation covers the list-to-net price bubble and why patients pay cost-sharing on a fictitious number, how the IRA's price-setting mechanism disincentivizes both new drug development and subsequent indications, and why the 340B program — sold politically as a lifeline for safety net hospitals — systematically funnels the most money to wealthy health systems with high commercial payer mixes. Long argues the fix isn't tweaking the formula; it's scrapping the drug arbitrage mechanism entirely and replacing it with a direct, transparent grant program that actually reaches the hospitals that need it.Chapter Markers00:00 Introduction — Ryan Long's 25 Years in Health Policy02:08 Drug Pricing 101: List Price vs. Net Price and Why It Matters06:39 GLP-1s as a Case Study: Insurance Pullback and the Price War That Followed11:17 The Medicare Bridge Program and Government Price Setting for GLP-1s14:11 Why Drug Companies Set List Prices High at Launch16:10 The Inflation Reduction Act: Price Controls, Rebate Penalties, and Innovation Risk20:57 Brand-to-Brand Competition and the FDA's Role28:52 GLP-1s Under Medicare: Is the $50/Month Bridge Program Good Policy?36:50 The Medicaid Drug Rebate Program and the Best Price Provision38:08 The Origins of 340B: What the Program Was Actually Designed to Do42:24 Qui Bono — How 340B Revenue Is Really Generated50:17 Contract Pharmacies and the For-Profit Middlemen in 340B56:31 The Humira Biosimilar Case and the Rebate Trap1:02:58 The 1987 Supreme Court Case That Supercharged the Rebate Structure1:05:26 Broad Reform Proposals: From 340B Overhaul to Consolidation1:09:19 Closing Thoughts and Where to Find Ryan's WorkCo-Host Handles@anish_koka and @drdigiorgioShow Handle@drsloungepodSubscribe LinksSpotify: https://open.spotify.com/show/44vw8eirsKKnjgNIrdDvrRApple Podcasts: https://podcasts.apple.com/us/podcast/the-doctors-lounge/id1832097658YouTube: https://www.youtube.com/@TheDoctorsLoungePod
What this episode covers
Episode SummaryRyan Long — former senior policy advisor to Speaker Kevin McCarthy and current non-resident senior scholar at the USC Schaefer Institute — joins Drs. Koka and DiGiorgio for a deep dive into the structural failures driving American drug pricing. The conversation covers the list-to-net price bubble and why patients pay cost-sharing on a fictitious number, how the IRA's price-setting mechanism disincentivizes both new drug development and subsequent indications, and why the 340B program — sold politically as a lifeline for safety net hospitals — systematically funnels the most money to wealthy health systems with high commercial payer mixes. Long argues the fix isn't tweaking the formula; it's scrapping the drug arbitrage mechanism entirely and replacing it with a direct, transparent grant program that actually reaches the hospitals that need it.Chapter Markers00:00 Introduction — Ryan Long's 25 Years in Health Policy02:08 Drug Pricing 101: List Price vs. Net Price and Why It Matters06:39 GLP-1s as a Case Study: Insurance Pullback and the Price War That Followed11:17 The Medicare Bridge Program and Government Price Setting for GLP-1s14:11 Why Drug Companies Set List Prices High at Launch16:10 The Inflation Reduction Act: Price Controls, Rebate Penalties, and Innovation Risk20:57 Brand-to-Brand Competition and the FDA's Role28:52 GLP-1s Under Medicare: Is the $50/Month Bridge Program Good Policy?36:50 The Medicaid Drug Rebate Program and the Best Price Provision38:08 The Origins of 340B: What the Program Was Actually Designed to Do42:24 Qui Bono — How 340B Revenue Is Really Generated50:17 Contract Pharmacies and the For-Profit Middlemen in 340B56:31 The Humira Biosimilar Case and the Rebate Trap1:02:58 The 1987 Supreme Court Case That Supercharged the Rebate Structure1:05:26 Broad Reform Proposals: From 340B Overhaul to Consolidation1:09:19 Closing Thoughts and Where to Find Ryan's WorkCo-Host Handles@anish_koka and @drdigiorgioShow Handle@drsloungepodSubscribe LinksSpotify: https://open.spotify.com/show/44vw8eirsKKnjgNIrdDvrRApple Podcasts: https://podcasts.apple.com/us/podcast/the-doctors-lounge/id1832097658YouTube: https://www.youtube.com/@TheDoctorsLoungePod
NOW PLAYING
Drug Pricing, Broken Incentives, and the 340b program Fixes Washington Won't Touch
No transcript for this episode yet
Similar Episodes
Dec 5, 2025 ·50m
Oct 9, 2025 ·33m
Oct 3, 2025 ·40m
Sep 11, 2025 ·31m
Aug 27, 2025 ·39m
Aug 18, 2025 ·54m